Phio Pharma gains as company says it can start patient enrollment for lead drug trial

Phio Pharmaceuticals

24/05/2023 13:28

** Drug developer Phio Pharmaceuticals Corp's  PHIO.O 
shares rise ~20% to $5.20 premarket
    ** Company says it can commence with patient enrollment for
trial of its lead drug PH-762 
    ** Phio says clinical development partner, AgonOx Inc, in
collaboration with Providence Cancer Institute, has completed
site initiation visit
    ** Trial will assess safety and potential of PH-762 in
patients with melanoma and other advanced solid tumors, Phio
says
    ** As of last close, company's shares down 2.8% YTD

 (Reporting by Sriparna Roy in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com))